RADEK SKODA to Alleles
This is a "connection" page, showing publications RADEK SKODA has written about Alleles.
Connection Strength
1.138
-
MPN patients with low mutant JAK2 allele burden show late expansion restricted to erythroid and megakaryocytic lineages. Blood. 2020 11 26; 136(22):2591-2595.
Score: 0.491
-
Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations. Blood. 2008 Apr 01; 111(7):3863-6.
Score: 0.201
-
Chronic myeloproliferative disorders--introduction. Semin Hematol. 2005 Oct; 42(4):181-3.
Score: 0.172
-
Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F. J Exp Med. 2014 Oct 20; 211(11):2213-30.
Score: 0.080
-
Differential effects of hydroxyurea and INC424 on mutant allele burden and myeloproliferative phenotype in a JAK2-V617F polycythemia vera mouse model. Blood. 2013 Feb 14; 121(7):1188-99.
Score: 0.071
-
The allele burden of JAK2 mutations remains stable over several years in patients with myeloproliferative disorders. Haematologica. 2008 Dec; 93(12):1890-3.
Score: 0.053
-
Clonal hematopoiesis in donors and long-term survivors of related allogeneic hematopoietic stem cell transplantation. Blood. 2020 04 30; 135(18):1548-1559.
Score: 0.029
-
JAK2 V617F-mutated myeloproliferative neoplasia developing five years after wild-type JAK2 acute myeloid leukemia: a case report. Acta Haematol. 2013; 129(1):23-5.
Score: 0.017
-
Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proc Natl Acad Sci U S A. 1988 Jul; 85(14):5240-3.
Score: 0.013
-
The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood. 2006 Sep 15; 108(6):1865-7.
Score: 0.011